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chestjournal.orgOBJECTIVE: The objective was to determine the relationship between short-term mortality
and intravenous morphine use in ED patients who received a diagnosis of acute heart failure
(AHF).
METHODS: Consecutive patients with AHF presenting to 34 Spanish EDs from 2011 to 2014
were eligible for inclusion. The subjects were divided into those with (M) or without IV
morphine treatment (WOM) groups during ED stay. The primary outcome was 30-day
all-cause mortality, and secondary outcomes were mortality at different intermediate time
points, in-hospital mortality, and length of hospital stay. We generated a propensity score to
match the M and WOM groups that were 1:1 according to 46 different epidemiological,
baseline, clinical, and therapeutic factors. We investigated independent risk factors for 30-day
mortality in patients receiving morphine.
RESULTS: We included 6,516 patients (mean age, 81 [SD, 10] years; 56% women): 416 (6.4%)
in the M and 6,100 (93.6%) in the WOM group. Overall, 635 (9.7%; M, 26.7%; WOM, 8.6%)
died by day 30. After propensity score matching, 275 paired patients constituted each group.
Patients receiving morphine had a higher 30-day mortality (55 [20.0%] vs 35 [12.7%] deaths;
hazard ratio, 1.66; 95% CI, 1.09-2.54; P ¼ .017). In patients receiving morphine, death was
directly related to glycemia (P ¼ .013) and inversely related to the baseline Barthel index and
systolic BP (P ¼ .021) at ED arrival (P ¼ .021). Mortality was increased at every intermediate
time point, although the greatest risk was at the shortest time (at 3 days: 22 [8.0%] vs 7 [2.5%]
deaths; OR, 3.33; 95% CI, 1.40-7.93; P ¼ .014). In-hospital mortality did not increase (39
[14.2%] vs 26 [9.1%] deaths; OR, 1.65; 95% CI, 0.97-2.82; P ¼ .083) and LOS did not differ
between groups (median [interquartile range] in M, 8 [7]; WOM, 8 [6]; P ¼ .79).
CONCLUSIONS: This propensity score-matched analysis suggests that the use of IV morphine
in AHF could be associated with increased 30-day mortality. CHEST 2017; 152(4):821-832KEY WORDS: acute heart failure; ED; morphine; opiates; outcomeheart failure; HR = hazard ratio; IQR =
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Morphine has largely been used to treat patients with
acute heart failure (AHF) with the most severe forms of
dyspnea, and especially in those presenting with acute
pulmonary edema.1,2 There are no large randomized
controlled trials supporting the use of morphine in the
treatment of patients with AHF. Physiological theory
to support its use is made on the basis of favorable
hemodynamic effects (reducing preload and, to a lesser
extent, afterload) and beneficial CNS actions (relieving
patient anxiety, breathlessness, restlessness, and chest
pain).3,4 However, these advantages may be overcome by
negative hemodynamic effects, particularly in patients
with previous volume depletion, as well as by deleterious
CNS depression and a reduction in ventilatory drive,
especially in patients with concurrent chronic
respiratory disease.3,4 In the scenario of AHF, therefore,Institut d’Investigacions Biomèdiques August Pi i Sunyer, Hospital
Clinic, Barcelona, Spain; Department of Emergency Medicine (Dr
Hollander), Sidney Kimmel Medical College at Thomas Jefferson
University, Philadelphia, PA; Department of Emergency Medicine (Dr
Peacock), Baylor College of Medicine, Houston, TX; and the Emer-
gency Department (Dr Llorens), Home Hospitalization and Short Stay
Unit, Hospital General de Alicante, Alicante, Spain.
FUNDING/SUPPORT: This study was partially supported by grants
from the Instituto de Salud Carlos III, which is supported with funds
from the Spanish Ministry of Health and Federación Española Enfer-
medades Raras [Grants PI10/01918, PI11/01021, PI15/01019, and
PI15/00773] and Fundació La Marató de TV3 (2015/2510). The
Emergencies: Processes and Pathologies Research Group of the Institut
d’Investigacions Biomèdiques August Pi i Sunyer receives financial
support from the Catalonian Government for Consolidated Groups of
Investigation [Grants GRC 2009/1385 and 2014/0313].
CORRESPONDENCE TO: Òscar Miró, MD, PhD, Emergency
Department, Hospital Clínic, Villarroel 170, 08036 Barcelona,
Catalonia, Spain; e-mail: omiro@clinic.cat
Copyright  2017 American College of Chest Physicians. Published by
Elsevier Inc. All rights reserved.
DOI: http://dx.doi.org/10.1016/j.chest.2017.03.037
822 Original Researchthe use of morphine remains largely controversial. The
American Heart Association/American College of
Cardiology only support the use of morphine for
palliative care in end-stage heart failure.5 The European
Society of Cardiology does not recommend routine use
of morphine, suggesting that it should only cautiously be
used in patients with severe dyspnea, and predominately
in those with pulmonary edema (recommendation
class IIB; level of evidence B).6 The main reason is the
controversy regarding the potentially elevated risk of
mortality in patients receiving morphine.7-9 Considering
the scarcity of data, we used propensity score (PS)
techniques to evaluate a large registry of consecutive
patients with AHF attended in the ED to ascertain
whether morphine use is associated with short-term
adverse outcomes.Patients and Methods
Study Setting
The present study was carried out in patients included in the
Epidemiology of Acute Heart Failure in Emergency Department
(EAHFE) Registry. This is a multicenter, observational,
multipurpose, cohort-designed database that includes consecutive
patients who received a diagnosis of AHF in 34 Spanish EDs in both
university and community hospitals from all areas of the country.
The characteristics of the EAHFE Registry have been published
elsewhere.10-12 For the present study, we used patients included in
the registry in 2011 (2 months of recruitment, 25 participating EDs,
n ¼ 3,414) and 2014 (2 months, 27 EDs, n ¼ 3,233). The
recruitment dynamics were the same in both periods. Briefly,
patients were included by the attending emergency physicians, all of
whom were given specific instructions about the study protocol
during a meeting held the week before each recruitment period in
every ED. All the cases identified were double-checked by the
principal investigator of each center who was blinded to the
treatment provided in the ED (including morphine) before inclusioninto the database to ascertain whether patients fulfilled the clinical
diagnostic criteria of AHF. In addition, when possible and available,
the diagnosis was confirmed by natriuretic peptide determination or
echocardiography following the European Society of Cardiology
criteria during ED or hospitalization stay6 (done in approximately
92% of cases). However, patients with clinical diagnostic criteria but
without ECG or natriuretic peptide determinations were accepted to
have a cohort as close as possible to what is observed in the routine
emergency medicine practice. Final diagnostic adjudication was done
by the principal investigator of the center. All principal investigators
were provided with a dictionary of terms to ensure common
definitions at all centers (e-Table 1). The only exclusion criterion in
the EAHFE Registry was patients who received a primary diagnosis
of ST elevation myocardial infarction who concurrently developed
AHF (which occurred in approximately 3% of AHF cases).
Variables Analyzed
In every patient, we collected 46 variables potentially related to
prognosis, including demographics, clinical history, presentation, and
treatments on the basis of the authors’ consensus after review of
previous literature.13-15 These variables were reported in specific case
report forms during ED attendance (e-Table 1). Interventions,
treatments, and patient allocation (hospital admission or discharge)
were entirely on the basis of the decisions of the attending
emergency physician. Subsequent follow-up by telephone contact and
consultation of medical records was performed between days 31 and
90 after ED attendance to detect all-cause death.
The entire EAHFE Registry protocol was approved by a single central
Ethical Committee at the Hospital Universitario Central de Asturias
(Oviedo, Spain; reference no. 49/2010). Because of the
noninterventional design of the study, Spanish legislation allowed the
remaining centers participating in a multicenter study to include
patients with central Ethical Committee approval, after duly
informing their local Ethical Committees about their participation.
All patients gave informed consent to be contacted for follow-up.
Around 2% of patients fulfilling the inclusion and exclusion criteria
refused to participate and did not sign informed consent.
Statistical Analysis
The classificatory variable was the use of IV morphine during the first
3 hours after ED arrival; thus, patients were divided into two groups on[ 1 5 2 # 4 CHES T OC TO B E R 2 0 1 7 ]
the basis of whether they were treated with morphine (M) or without
morphine (WOM). Thereafter, we investigated if there were any
differences in the distribution of the 46 independent variables
collected in the present study. With this proposal, we used c2 or the
Student t tests (or Mann-Whitney U test when appropriate)
depending on whether the variables were qualitative or quantitative,
respectively.
After this first approach, we used PS matching analysis to analyze two
comparable cohorts: with or without the use of morphine. A PS was
estimated for each of the patients16 using multivariate logistic
regression. The PS determines the probability that participants would
receive morphine on the basis of their individual characteristics
(covariates). We constructed a multivariable model including the
independent variables that significantly differed between groups
(defined as a P < .05), as well as age and sex, which, a priori, the
authors decided should be included irrespective of the P value. A PS
was then obtained for every patient on the basis of discordant
epidemiological, baseline, clinical, and therapeutic factors. This
method provides accurate estimates of the effect of a drug in
observational settings by minimizing confounding factors by
indication17 and has been proposed as a solution to overcome
immortal time bias (from the patient’s entrance into the cohort to
the study drug intake) in pharmacologic and epidemiological6,647 patients diagnos
6,598 patients diagno
whom use of morphin
6,516 patients diagno
whom use of morphin
and outcome 
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Figure 1 – Flow chart of patient inclusion in the present study. AHF ¼ acu
chestjournal.orgstudies.18 Finally, patients were paired (1:1) on the basis of a
maximum standardized difference of 1% in the PS.
The primary outcome of the present study was time to all-cause death
within 30 days after admission in PS-matched patients. The primary
end point was described using Kaplan-Meier survival curves, and we
used a log-rank test to compare the two curves. Risk of all-cause death
was calculated by estimation of hazard ratios (HRs) with 95% CI.
Subgroup analyses of the primary outcome was planned a priori for
sex, age, and use of vasoactive drugs (levosimendan, dopamine,
dobutamine, or noradrenaline) or ventilatory support (noninvasive or
invasive) in the ED; interaction was assessed by Cox models. As
sensitivity analyses, we estimated the risk of all-cause mortality at 3, 7,
and 14 days and in-hospital mortality (calculated by including both
patients who died during hospitalization and while in the ED before
hospitalization) by means of OR and their 95% CI. Additionally,
differences in length of stay (LOS) were also calculated for hospitalized
patients discharged alive. Finally, for patients included in the M group
of the PS analysis, we investigated independent factors associated with
the primary end point (30-day mortality) by including all variables
with a statistically significant different distribution in the univariate
analysis in a logistic regression model (enter mode). All statistical tests
were performed with a two-sided type I error of 5%; we used statistical
software (SPSS v 19.0) for all the calculations.Results
Of the 6,647 patients initially included in the EAHFE
Registry, 131 were excluded from analysis (49 without
recorded morphine use and 82 lost to follow-up), leaving
6,516 for analysis in the present study. Overall, 416
patients (6%) were included in the M and 6,100 (94%) inthe WOM groups (Fig 1). Comparisons between the
two groups are presented in Table 1, with differences in
24 of the 46 baseline study variables. Patients in the
M group had higher rates of ischemic heart disease,
cerebrovascular disease, peripheral artery disease, and
dementia, but were less likely to have chronic lunged with AHF
49 patients use of morphine not recorded
82 patients lost at follow-up
sed with AHF for
e was recorded




Without Morphine (WOM) Group
6,100 patients did not receive morphine





TABLE 1 ] Characteristics of the 6,516 Patients in the Raw Analysis of This Study and the 550 Patients Matched by a PS; Comparison Between Patients With M






















Dead After 30 d
n ¼ 55
No. (%)




Age, mean (SD) 80.6 (9.8) 80.6 (10.2) 80.1 (9.9) .33 80.7 (10.2) 81.1 (10.1) .66 85 (9) 80 (10) .001
Women 3,662 (56.4) 248 (59.9) 3,414 (56.1) .15 118 (42.9) 117 (42.5) 1.00 32 (58.2) 125 (56.8) .98
Comorbidities
Arterial hypertension 5,513 (84.6) 347 (83.6) 5,166 (84.7) .59 231 (84.0) 250 (90.9) .02 47 (85.5) 184 (83.6) .90
Diabetes mellitus 2,742 (42.1) 193 (46.5) 2,549 (41.8) .07 126 (45.8) 140 (50.9) .27 23 (41.8) 103 (46.8) .61
Dyslipidemia 2,870 (44.1) 170 (41.0) 2,700 (44.3) .20 108 (39.3) 129 (46.9) .09 19 (34.5) 89 (40.5) .52
Ischemic heart disease 1,948 (29.9) 153 (36.9) 1,795 (29.4) .002 100 (36.4) 102 (37.1) .93 18 (32.7) 82 (37.3) .64
Chronic kidney failure 1,632 (25.1) 108 (26.1) 1,524 (25.0) .66 72 (26.2) 71 (25.8) 1.00 17 (30.9) 55 (25.0) .47
Cerebrovascular disease 871 (13.4) 80 (19.3) 791 (13.0) < .001 50 (18.2) 48 (17.5) .91 6 (10.9) 44 (20.0) .17
Atrial fibrillation 3,166 (48.6) 158 (38.1) 3,008 (49.3) < .001 123 (44.7) 108 (39.3) .23 18 (32.7) 105 (47.7) .06
Peripheral arterial disease 592 (9.1) 53 (12.8) 539 (8.8) .009 42 (15.3) 32 (11.6) .26 9 (16.4) 33 (15.0) .97
Cardiac valve disease 1,840 (28.3) 116 (28.0) 1,724 (28.3) .93 71 (25.8) 76 (27.6) .70 13 (23.6) 58 (26.4) .81
COPD 1,673 (25.7) 87 (21.0) 1,586 (26.0) .026 60 (21.8) 58 (21.1) .92 11 (20.0) 49 (22.3) .85
Dementia 850 (13.1) 71 (17.1) 779 (12.8) .01 41 (14.9) 44 (16.0) .81 11 (20.0) 30 (13.6) .33
Active cancer 859 (13.2) 63 (15.2) 796 (13.1) .24 42 (15.3) 34 (12.4) .39 9 (16.4) 33 (15.0) .97
Prior episode of heart failure 3,764 (58.4) 241 (58.4) 3,523 (58.4) 1.00 162 (59.1) 167 (61.4) .65 35 (63.6) 127 (58.0) .54
Pacemaker or defibrillator 479 (7.7) 23 (6.4) 339 (7.8) .36 17 (6.2) 21 (7.6) .61 2 (3.6) 15 (6.8) .57
Basal situation
Barthel index points, mean
(SD)
79 (24) 73 (28) 80 (24) < .001 72 (29) 74 (26) .30 54 (33) 77 (26) < .001
Cardiorespiratory (NYHA
III-IV)
1426 (23.8) 123 (31.7) 1,303 (23.3) < .001 88 (32.1) 92 (33.5) .81 25 (46.3) 62 (29.2) .03
Chronic treatment at home
Loop diuretics 4,276 (69.1) 210 (58.0) 4,066 (69.8) < .001 168 (61.1) 171 (62.2) .86 36 (65.5) 132 (60.0) .56
Thiazide diuretics 792 (12.8) 49 (13.5) 743 (12.8) .73 37 (13.5) 38 (13.8) 1.00 7 (12.7) 30 (13.6) 1.00
Aldosterone-receptor
antagonists
1,123 (18.2) 52 (14.4) 1,071 (18.4) .06 42 (15.3) 40 (14.5) .90 6 (10.9) 36 (16.4) .43
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1,514 (24.5) 94 (26.0) 1,420 (24.4) .54 76 (27.6) 70 (25.5) .63 9 (16.4) 67 (30.5) .06
Beta-blocker 2400 (38.8) 144 (39.8) 2,256 (38.7) .74 106 (38.5) 104 (37.8) .93 16 (29.1) 90 (40.9) .14
Nitrates 1,144 (18.5) 91 (25.1) 1,053 (18.1) .001 73 (26.5) 70 (25.5) .85 16 (29.1) 57 (25.9) .76
Digoxin 1,037 (16.8) 47 (13.0) 990 (17.0) .05 42 (15.3) 40 (14.5) .90 7 (12.7) 35 (15.9) .71
Amiodarone 386 (6.2) 30 (8.3) 356 (6.1) .12 23 (8.4) 12 (4.4) .08 7 (12.7) 16 (7.3) .30
Antiplatelets 2,339 (37.8) 158 (43.6) 2,181 (37.5) .02 113 (41.1) 119 (43.3) .65 23 (41.8) 90 (40.9) 1.00
Anticoagulants 1,446 (23.4) 63 (17.4) 1,363 (23.8) .006 53 (19.3) 69 (25.1) .12 15 (27.3) 38 (17.3) .14
Vitals at ED arrival, mean (SD)
Systolic BP (mm Hg) 142 (28) 152 (37) 141 (27) < .001 153 (35) 154 (34) .71 135 (36) 158 (33) < .001
Heart rate (beats/min) 89 (25) 99 (27) 88 (24) < .001 99 (28) 96 (25) .20 89 (22) 101 (28) .004
Basal oxygen saturation (%) 92 (7) 88 (24) 92 (6) < .001 88 (9) 88 (11) .82 85 (12) 89 (9) .001
Temperature (C) 36.2 (0.7) 36.2 (0.7) 36.2 (0.7) .17 36.2 (0.6) 36.2 (0.6) .44 36.3 (0.8) 36.2 (0.6) .13
ECG
Atrial fibrillation 3,047 (47.5) 158 (38.9) 2,889 (48.1) < .001 120 (44.0) 114 (41.8) .66 18 (32.1) 102 (46.8) .08
Left ventricular hypertrophy 184 (2.9) 21 (5.2) 163 (2.7) .006 14 (5.1) 6 (2.2) .11 1 (1.8) 13 (6.0) .36
Left or right bundle-branch
block
579 (9.0) 66 (16.3) 513 (8.5) < .001 49 (17.9) 31 (11.4) .04 10 (18.2) 39 (17.9) 1.00
Laboratory results at ED, mean
(SD)
Glucose (mg/dL) 148 (68) 192 (87) 146 (67) < .001 185 (81) 194 (101) .27 206 (91) 180 (77) .03
Creatinine clearance (mL/
min/m2)
59 (28) 54 (26) 60 (28) < .001 56 (27) 58 (28) .43 52 (23) 57 (28) .29
Sodium (mmol/L) 138 (5) 138 (6) 138 (5) .86 138 (6) 137 (5) .17 137 (7) 138 (5) .08
Potassium (mmol/L) 4.40 (0.67) 4.51 (0.80) 4.41 (0.68) .03 4.48 (0.72) 4.47 (0.71) .90 4.7 (0.9) 4.4 (0.7) .01
Hemoglobin (g/L) 119 (20) 121 (21) 120 (21) .26 122 (22) 119 (21) .14 121 (21) 121 (21) .84
Intensive treatment at ED









































































































































































































































































































































































































































































































826 Original Researchdisease. They also showed a worse functional status, with
a higher New York Heart Association class III-IV. In
regard to outpatient treatment, patients in the M group
less often received loop diuretics and anticoagulants, but
more frequently received nitrates and antiplatelet agents.
At ED arrival, systolic BP and heart rate were higher and
room-air pulse oximetry lower in the M cohort. Patients
in the M group more often had ECG findings of left
ventricular hypertrophy and left or right bundle-branch
block but less frequently had atrial fibrillation. Initial ED
laboratory values of both glucose and potassium were
higher, although creatinine values were lower in the M
cohort. Finally, patients in the M group were more likely
to receive IV nitrates, vasoactive drugs, noninvasive
ventilation, and any kind of ventilatory support. In the
entire cohort, 635 (9.7%) patients died within 30 days
after ED attendance: 26.7% vs 8.6%, respectively, in the
M and WOM groups (P < .001).
The PS was finally calculated using the 24 significant
baseline variables; thus, the medians (interquartile
range [IQR]) of the predicted probabilities of receiving
morphine in patients in the M and WOM groups were
19.2% (39.9) and 2.1% (2.9), respectively (P < .001). On
the basis of these predicted probabilities, PS matching
provided 275 balanced paired cases. The only significant
differences among these cases were the prevalence of
arterial hypertension, which was more frequent in the
WOM group, and right or left bundle-branch block,
which was more frequent in the M group (Table 1). The
medians of predicted probability of receivingmorphine in
the M and WOM PS-matched groups were 15.6% (IQR,
32.2) and 16.5% (IQR, 31.7), respectively (P ¼ .96).
Overall, 90 patients (16.4%)died at 30 days in thePS-based
analysis: 6 in the ED during the first 24 hours after ED
arrival (five deaths from refractory heart failure and one
frommassive bleeding caused by overanticoagulationwith
acenocoumarol; these six patients had been previously
ruled out for ICU admission because of comorbidity,
severe baseline functional disabilities, and/or advanced
age), two at home after direct discharge from the ED (one
from refractory heart failure and one from hypovolemic
shock); 56 died during hospital admission, and 26 died
after hospital discharge. The six patients who died in the
ED were in the M group (P ¼ .030) (Table 2).
Among the 90 deaths, 55 were in the M group and 35
in the WOM group (20.0% vs 12.7%, respectively;
P ¼ .028). Survival analysis of the PS-matched patients
showed a significant increase in 30-day mortality in the
M group (HR, 1.66; 95% CI, 1.09-2.54; P ¼ .017) (Fig 2),[ 1 5 2 # 4 CHES T OC TO B E R 2 0 1 7 ]
TABLE 2 ] Description of Patients Who Died Included in the PS Analysis
All Deaths (N ¼ 90) M Group (n ¼ 55) WOM Group (n ¼ 35)
Specific conditions of M use
M used during NIV (%)a 8 (9.4) 8 (16.0) .
M used to treat ACS (%)a 6 (7.1) 6 (12.0) .
Conceptual interval at which death occurred
At ED (before hospitalization) (%) 6 (6.7) 6 (10.9) 0 (0)
After direct ED discharge (%) 2 (2.2) 2 (3.7) 0 (0)
During hospitalization (%) 56 (62.2) 32 (58.1) 24 (68.9)
After discharge from hospitalization (%) 26 (28.9) 15 (27.3) 11 (31.1)
Cause of death
Refractory heart failure (%) 55 (61.1) 35 (63.6) 20 (57.1)
Other cardiovascular (%) 7 (7.7) 3 (5.5) 4 (11.4)
Noncardiovascular origin 15 (16.7) 6 (10.9) 9 (25.7)
Unknown (%) 13 (14.4) 11 (20.0) 2 (5.7)
Death at home (%)b 11 (12.4) 9 (16.4) 2 (5.9)
ACS ¼ acute coronary syndrome; NIV ¼ noninvasive ventilation. See Table 1 legend for expansion of other abbreviations.
aThis information was not available in 5 patients.
bThis information was not available in 1 patient.and mortality was increased at 3, 7, and 14 days, with the
greatest OR being found at the shortest post-ED time



































Figure 2 – Analysis of primary outcome using survival curves for propensity s
HR ¼ hazard ratio.
chestjournal.org3 days. In-hospital mortality in the M group was higher
than in the WOM group, although without statistical































orphine Group [n = 275; HR 1 (reference)]
roup [n = 275; HR 1.66 (95% CI 1.09-2.54)]
core-matched patients treated with and without IV morphine in the ED.
827
P ¼ .083) (Fig 3). The median hospital LOS in the
patients discharged alive did not differ between the M
and WOM groups: 8 (IQR, 7) and 8 (IQR, 6) days
(P ¼ .79), respectively. Patients receiving morphine who
died differed from those who survived in nine variables
(Table 1). However, only 3 of these variables were
independent predictors of 30-day mortality: glycemia
(P ¼ .013) had a direct relationship; the baseline Barthel
index (P ¼ .021) and systolic BP (P ¼ .021) at ED arrival
had an inverse relationship.
Preplanned subgroup analyses showed that the increased
risk of short-term mortality only differed with respect to
age, but not sex, and the use of vasoactive drugs or
ventilatory support in the ED (Fig 4).
Discussion
On the basis of a PS-matched analysis, the most relevant
finding of our study was that the use of IV morphine in
patients with AHF in the ED is associated with a greater
risk of 30-day mortality. We observed an increased risk
of mortality at all the time points measured and found
that the risk of death associated with morphine use was
especially high at the shortest time points, as predicted
by the pharmacokinetics of the drug. No relationship
was found between morphine use in the ED and either
in-hospital mortality or LOS in patients who survived
hospital admission and were discharged.
Our results are in line with the latest recommendations
of the American Heart Association/American College
of Cardiology and European Society of Cardiology,
which restrict the use of opiates in AHF.5,6,19,20 In fact,
during the past several years, international guidelines
have moved from positions of opiate recommendation
for well-defined clinical scenarios to this current
position. The main reason for this shift in position is the
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Figure 3 – Analysis of secondary end points regarding intermediate mortalit
morphine in the ED.
828 Original Researchmorphine use on patient outcomes.21 together with
studies that suggest an increased risk of mortality.
Historically, data to support guideline recommendations
were only obtained from small studies that were not
adjusted for confounding factors, especially for the
severity of AHF presentation. Because opiates were
more frequently used in the setting of acute severe
presentations, the increased mortality in this subgroup
could not distinguish between an increased risk of death
from severe disease or from treatment.22-25 However,
three larger studies have enlightened the current
recommendations. In the largest study to date, Peacock
et al7 reported data from the Acute Decompensated
Heart Failure Registry, including nearly 150,000 patients
admitted to US acute care hospitals for AHF. Of these,
14% were treated with morphine at some point of
time during hospitalization. Those treated with
morphine showed a greater in-hospital mortality, even
after risk adjustment and exclusion of ventilated patients
(OR, 4.84; 95% CI, 4.52-5.18). Conversely, Gray et al9
performed a secondary analysis of 1,052 patients
included in the UK Three Interventions in Cardiogenic
Pulmonary Oedema (3CPO) trial carried out from
2003 to 2007. Although there was no correlation
between the use of morphine and improvement in
respiratory distress or patient-perceived breathlessness
over the first hour, they failed to find any relationship
between morphine and 7-day mortality.9 Because the
3CPO study was undertaken in the emergency setting
and included more severe forms of AHF, the conditions
of morphine use might have differed from those of
hospital admission, as suggested by the fact that
51% of the patients received morphine. Finally, in a
retrospective analysis of 2,336 Israeli patients hospitalized
in cardiology or internal medicine wards, 9% of whom
received morphine, Iakobishvili et al8 found an increased
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Hazard ratio for 30-day mortality (95% CI)
For patients receiving morphine at ED
Figure 4 – Sensitivity analysis stratifying 30-day mortality risk by sex, age, need for ventilatory support, and vasoactive drugs for propensity score-
matched patients treated with and without IV morphine in the ED.did not remain significant after PS-matching of 218
paired patients (OR, 1.2; 95% CI, 0.6-2.4).
We believe that the current study adds some relevant
insight to previous studies in the literature. First, it
evaluates the effect of IV morphine in the emergency
arena at very early stages of AHF treatment. This ED
use of morphine may be markedly different than in
admitted patients, in whom a fixed dose can be added.
In the present study, we recorded the use of morphine
in the ED during the first 3 hours of the initial patient
treatment, at which time morphine is usually given in
boluses as needed. Because the indication for morphine
suggests that it is only administered to patients with
the greatest disease severity, studies evaluating its
usage are rarely approved, randomized, or placebo-
controlled. This produces a scenario in which PS
matching using retrospective data can provide insight
and guidance to presentations for which there would
be little evidence-based data. Second, we included all
patients with AHF and not only those admitted to
hospital. Because some patients can die early in the ED,
before admission to hospital (as occurred in six of
patients), analysis limited to admitted patients may
incur some kind of bias. And third, because we
included practically all types of patients who received
a diagnosis of AHF (only those with ST elevation
myocardial infarction were excluded in the present
series) and not those specifically admitted to ICUs
or cardiology wards (as occurs in other series), the
patients analyzed in the present study corresponded to
a population with substantial differences in the baseline
characteristics and outcomes compared with those
included in previous studies. Some authors havechestjournal.orgadvocated this multidisciplinary approach, involving
different specialties, because it would allow a wider
spectrum of patients with heart failure to be covered.26,27
It is well known that the aforementioned specialties
admit younger patients, for whom there is usually no
limitation in the therapeutic approaches implemented.
Conversely, the universe of AHF (which is better
represented in the ED, where practically all patients with
a decompensation consult) includes patients with
advanced forms of cardiomyopathy, severe functional
impairment, and many comorbidities. Our sample is
quite representative of this universe because the mean
age of patients was 81 years, comorbidities were
frequent, and up to 26% of patients had a Barthel
index < 60 (severe functional limitation), all being
clearly higher than in the three previously mentioned
studies in this same field.7-9 In addition, most of the
patients did not fulfill the criteria for ICU admission;
this could explain why our mortality rates were higher
than those described in previous studies.7-9
It is interesting to note that our results showed an increase
in the overall short-term mortality but no changes in
in-hospital mortality or hospital LOS. With respect to the
first, there may have been a type II error, because PS
matched only 275 pairs of patients, leaving quite a small
sample size, and comparison of in-hospital mortality
was close to demonstrating a significant increase, which
would be in line with increased mortalities in short-term
comparisons. With respect to hospital LOS, we believe
that this could be partially influenced by the fact that,
according to study definition, we included only patients
admitted to hospital and discharged alive in the
calculation of this secondary end point.829
On the other hand, we found that some of the most
severely ill patients died in the ED while awaiting a
hospital bed, and none of these patients was considered
a candidate for admission to an ICU. Although it was
not recorded, compassionate morphine use may have
been administered to some of these patients, which
would explain the greater mortality observed in the
early stage of AHF. Nonetheless, although the increase
in the very short-term mortality (especially at 3 days)
found in the present study could potentially be
explained by physicians having given morphine to
patients with greater baseline disease, PS matching
should have identified a cohort with similar baseline
risks. This suggests that morphine use may have some
yet-to-be-identified mechanisms associated with short-
term death. It remains unclear whether this is the
result of a prolonged adverse cardiovascular effect,
modulation of receptor sensitivity, respiratory drive
inhibition, or chronic negative inotropic action.
However, the net result is an association with short-
term death (and especially with very short-term
mortality at 3 days), which makes it difficult to support
this therapy. It was also of note that we found an
interaction with respect to age, and a higher mortality
was associated with morphine use in patients with 80
years of age or younger. The possibility that the effects
of morphine use are the most deleterious in patients
most likely to survive (younger patients) is of great
concern. On the other hand, once morphine is given,
factors related to higher mortality were advanced
age, limited baseline functional status (shown by the
Barthel index), and decreased blood pressure at ED
arrival, all of which are well-known general factors
with an effect on the prognosis of patients with severe
acute conditions.
Although this is one of the largest evaluations of the use
of morphine in AHF to date, it has important
limitations. First, as a retrospective uncontrolled
evaluation, insight into our conclusion must be limited
to the generation of hypotheses but, remarkably, our
results are consistent with prior AHF analyses
suggesting that, in the absence of a documented benefit,
routine morphine use should be avoided. Second, in830 Original Research8% of patients, a diagnosis of AHF was exclusively on
the basis of clinical criteria, but this is a pragmatic
approach that reproduces what is happening in many
EDs worldwide. Third, the total dose of morphine
administered to each patient was not quantified; thus,
we could not determine whether the higher mortality
rate was related to higher doses of morphine. Fourth,
although we were able to identify the use of morphine
in patients with chest pain or those undergoing
noninvasive ventilation, we failed to identify whether
morphine use was palliative in some cases. However,
because we only recorded the use of morphine during
the first 3 hours after patient arrival to the ED, palliative
use was most likely low. Fifth, as in any study carried
out in a single country, extrapolation of the results at an
international level should be made with caution.
Additionally, Spanish EDs participating in the EAHFE
Registry were not randomly selected, but rather were
members of the Acute Heart Failure Study Group of
the Spanish Society of Emergency Medicine research
network, with special interest in AHF; thus, the results
could differ when applied to other EDs. Sixth, PSs
are widely used to overcome the bias shown in
observational studies when a specific treatment is
analyzed because they match the population according
to the main covariates. The PS is a validated method
for the identification of trends, but strong conclusions
cannot be made because hidden confounders in
some covariates may not be included in the analysis;
therefore, the results with this methodology should be
taken with caution and considered, as in the present
study, as the generation of a hypothesis that should be
confirmed in clinical trials. Indeed, a current ongoing
randomized clinical trial could eventually answer this
question.28
In conclusion, our data suggest that the use of morphine
in ED patients who have received a diagnosis of AHF is
associated with an increased 30-day mortality, and that
this increased risk is especially higher during the first
3 days. With few data to support the use of morphine in
this cohort, we suggest that its use in AHF patients
should be curtailed until further data demonstrating
safety become available.[ 1 5 2 # 4 CHES T OC TO B E R 2 0 1 7 ]
Acknowledgments
Author contributions: The study was
conceived by O. M., V. G., and P. L.; the
design was carried out by O. M., F. J. M.-S.,
and J. R.; the patient inclusion was done by
O. M., V. G., F. J. M.-S., and P. L.; data
analysis was performed by O. M., J. R.,
V.-P. H., and W. F. P.; primary discussion
of results was done by O. M., V. G., J. R.,
V.-P. H., J. E. H., and W. F. P.; the first
draft was written by O. M.; all authors
participated in the discussion, gave
substantial input to the paper content, revised
and approved the successive versions of the
paper during the editorial review process, and
gave approval for the final version. O. M.
takes responsibility for the entire manuscript.
Financial/nonfinancial disclosures: The
authors have reported to CHEST the following:
J. E. H. has research grant support from Alere,
Trinity, Roche, and Siemens. The ICA-SEMES
Research Group has received unrestricted
support from Orion Pharma and Novartis.
Nonedeclared (O.M.,V.G., F. J.M.-S., P.H.-P.,
J. J., A. M., V.-P. H., J. R., W. F. P., P. L.).
Role of sponsors: The sponsor had no role in
the design of the study, the collection and
analysis of the data, or the preparation of the
manuscript.
*Writing Committee Members for the
ICA-SEMES research group: Marta Fuentes,
Cristina Gil (Hospital Universitario de
Salamanca); María José Pérez-durá, Eva
Salvo, José Vallés (Hospital La Fe de
Valencia); Rosa Escoda, Carolina Xipell,
Carolina Sánchez (Hospital Clinic de
Barcelona); José Pavón, Ana Bella Álvarez
(Hospital Dr. Negrín de Las Palmas de Gran
Canaria); Antonio Noval (Hospital Insular de
Las Palmas de Gran Canaria); José M. Torres
(Hospital Reina Sofía de Córdoba); Maria
Luisa López-Grima, Amparo Valero
(Hospital Dr. Peset de Valencia); Alfons
Aguirre, MariaÀngelsPedragosa (Hospital del
Mar de Barcelona); Maria Isabel Alonso,
Helena Sancho, Paco Ruiz (Hospital de
Valme de Sevilla); Antonio Giménez, José
Miguel Franco (Hospital Miguel Servet de
Zaragoza); Sergio Pardo (Hospital San Juan
de Alicante); Ana Belen Mecina (Hospital de
Alcorcón); Josep Tost (Consorci Sanitari de
Terrassa); Jordi Fabregat (Hospital Mutua de
Terrasa); Susana Sánchez (Hospital Rio
Ortega de Valladolid); Pascual Piñera
(Hospital Reina Sofia de Murcia); Raquel
Torres Garate (Hospital Severo Ochoa); Aitor
Alquezar, Miguel Alberto Rizzi (Hospital San
Pau de Barcelona); Fernando Richard
(Hospital de Burgos); Javier Lucas (Hospital
General de Albacete); Irene Cabello, Álex
Roset (Hospital Universitari de Bellvitge,
Barcelona); Esther Rodríguez-Adrada,
Guillermo Llopis García (Hospital Clínico
San Carlos, Madrid); José Manuel Garrido
(Hospital Virgen de la Macarena, Sevilla).
Additional information: The e-Table can be
found in the Supplemental Materials section
of the online article.chestjournal.orgReferences
1. Llorens P, Escoda R, Miró O, et al.
Characteristics and clinical course of
patients with acute heart failure and the
therapeutic measures applied in Spanish
emergency departments: based on the
EAHFE registry (Epidemiology of Acute
Heart Failure in Emergency Departments).
Emergencias. 2015;27:11-22.
2. Sosnowski MA. Review article: lack of
effect of opiates in the treatment of acute
cardiogenic pulmonary oedema. Emerg
Med Australas. 2008;20(5):384-390.
3. Alison RC. Initial treatment of pulmonary
edema: a physiological approach. Am J
Med Sci. 1991;302(6):385-391.
4. Johnson MJ, McDonagh TA,
Harkness A, McKay SE, Dargie HJ.
Morphine for the relief of breathlessness
in patients with chronic heart failure- a
pilot study. Eur J Heart Fail. 2002;4(6):
753-756.
5. Yancy CW, Jessup M, Bozkurt B, et al.
2016 ACC/AHA/HFSA Focused Update
on New Pharmacological Therapy for
Heart Failure: An Update of the 2013
ACCF/AHA Guideline for the
Management of Heart Failure: a report of
the American College of Cardiology/
American Heart Association Task Force
on Clinical Practice Guidelines and the
Heart Failure Society of America. J Am
Coll Cardiol. 2016;22(9):659-669.
6. Ponikowski P, Voors AA, Anker SD, et al.
2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart
failure: the Task Force for the diagnosis
and treatment of acute and chronic heart
failure of the European Society of
Cardiology (ESC). Developed with the
special contribution of the Heart Failure
Association (HFA) of the ESC. Eur Heart
J. 2016;18(8):891-975.
7. Peacock WF, Hollander JE, Diercks DB,
Lopatin M, Fonarow G, Emerman CL.
Morphine and outcomes in acute
decompensated heart failure: an ADHERE
analysis. Emerg Med J. 2008;25(4):
205-209.
8. Iakobishvili Z, Cohen E, Garty M, et al.
Use of intravenous morphine for acute
decompensated heart failure in patients
with and without acute coronary
syndromes. Acute Card Care. 2011;13(2):
76-80.
9. Gray A, Goodacre S, Seah M, Tilley S.
Diuretic, opiate and nitrate use in severe
acidotic acute cardiogenic pulmonary
oedema: analysis from the 3CPO trial.
QJM. 2010;103(8):573-581.
10. Miró Ò, Gil V, Müller C, et al. How does a
clinical trial fit into the real world? The
RELAX-AHF study population into the
EAHFE registry. Clin Res Cardiol.
2015;104(10):850-860.
11. Miró O, Escoda R, Martín-Sánchez FJ,
et al. Patients’ perception of quality of
emergency department care for acute
heart failure: the CALPERICA study.
Emergencias. 2015;27:161-168.12. Miró Ò, Müller C, Martín-Sánchez FJ,
et al. BETAWIN-AHF study: effect of
beta-blocker withdrawal during acute
decompensation in patients with chronic
heart failure. Clin Res Cardiol.
2016;105(12):1021-1029.
13. Peacock WF, Nowak R, Christenson R,
et al. Short-term mortality risk in
emergency department acute heart failure.
Acad Emerg Med. 2011;18(9):947-958.
14. Teixeira A, Parenica J, Park JJ, et al.
Clinical presentation and outcome by
age categories in acute heart failure: results
from an international observational
cohort. Eur J Heart Fail. 2015;17(11):
1114-1123.
15. Herrero-Puente P, Martín-Sánchez FJ,
Fernández-Fernández M, et al.
Differential clinical characteristics and
outcome predictors of acute heart failure
in elderly patients. Int J Cardiol.
2012;155(1):81-86.
16. Normand SL, Sykora K, Li P, Mamdani M,
Rochon PA, Anderson GM. Readers guide
to critical appraisal of cohort studies: 3.
Analytical strategies to reduce confounding.
BMJ. 2005;330(7498):1021-1023.
17. Tannen RL, Weiner MG, Xie D. Use of
primary care electronic medical record
database in drug efficacy research on
cardiovascular outcomes: comparison of
database and randomised controlled trial
findings. BMJ. 2009;338:b81.
18. Zhou Z, Rahme E, Abrahamowicz M,
Pilote L. Survival bias associated with
time-to-treatment initiation in drug
effectiveness evaluation: a comparison of
methods. Am J Epidemiol. 2005;162(10):
1016-1023.
19. Mebazaa A, Yilmaz MB, Levy P, et al.
Recommendations on pre-hospital &
early hospital management of acute
heart failure. Eur J Heart Fail.
2015;17(6):544-558.
20. Llorens P, Manito Lorite N, et al.
Consensus on improving the care
integrated of patients with acute heart
failure. Emergencias. 2015;27:245-266.
21. Domínguez-Rodríguez A, Abreu-
González P.Morphine for acute pulmonary
edema? Emergencias. 2016;28:418-420.
22. Hoffman JR, Reynolds S. Comparison of
nitroglycerin, morphine and furosemide
in treatment of presumed pre-hospital
pulmonary edema. Chest. 1987;92(4):
586-593.
23. Beltrame JF, Zeitz CJ, Unger SA, et al. Nitrate
therapy is an alternative to furosemide/
morphine therapy in the management of
acute cardiogenic pulmonary edema. J Card
Fail. 1998;4(4):271-279.
24. Sacchetti A, Ramoska E, Moakes ME,
McDermott P, Moyer V. Effect of ED
management on ICU use in acute
pulmonary edema. Am J Emerg Med.
1999;17(6):571-574.
25. Fiutowski M, Waszyrowski T,
Krzeminska-Pakula M, Kasprzak JD.
Clinical presentation and pharmacological
therapy in patients with cardiogenic831
pulmonary oedema. Kardiol Pol. 2004;61.
561-556.
26. Bueno H. Cardiovascular research
continuity: a call for greater collaboration
between cardiology and emergency care
researchers. Emergencias. 2015;27:396-398.832 Original Research27. Antonini P, Magrini L, Murphy M, Di
Somm S. Multidisciplinary research in
emergency medicine. Emergencias.
2015;27:399-402.
28. Domínguez-Rodríguez A, Burillo-
Putze G, García-Saiz MM, et al. Study[
design and rationale of “A Multicenter,
Open-Labeled, Randomized Controlled
Trial Comparing MIdazolam versus
MOrphine in Acute Pulmonary Edema:”
MIMO trial. Cardiovasc Drugs Ther.
2017;31(2):209-213.1 5 2 # 4 CHES T OC TO B E R 2 0 1 7 ]
